Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immatics NV (NQ: IMTX )

12.62 +0.05 (+0.44%)
Streaming Delayed Price Updated: 1:27 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,653
Open 12.62
Bid (Size) 12.58 (5)
Ask (Size) 12.65 (4)
Prev. Close 12.56
Today's Range 12.61 - 12.79
52wk Range 7.150 - 13.77
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga

Performance

YTD
+17.68%
+17.68%
1 Month
-3.04%
-3.04%
3 Month
+21.30%
+21.30%
6 Month
+4.34%
+4.34%
1 Year
+11.54%
+11.54%

More News

Read More
Immatics Announces First Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Why Immatics Shares Are Rising Today
Via Benzinga
Recap: Immatics Q1 Earnings
Via Benzinga
Why Immatics Stock Is Soaring Today
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
From https://immatics.com/
Via GlobeNewswire
Top 5 Health Care Stocks That May Crash This Month
Via Benzinga
Immatics Announces First Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
What's Going On With Immatics Shares Today
Via Benzinga
US Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT Concerns
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.